Pharmacist Enhanced Service for Cardiovascular Risk Reduction
NCT ID: NCT04220788
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2020-03-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
NCT06405880
Mobile Cardiovascular Risk Service Trial
NCT03081871
Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control
NCT07228065
Patient-Centered Pharmacist Care in the Hemodialysis Unit: A Quasi-Experimental Interrupted Time Series Study
NCT03576404
Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
NCT06647238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enhanced pharmacist service
The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
Enhanced pharmacist service
Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
Usual care
Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
Usual care
Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enhanced pharmacist service
Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
Usual care
Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with chronic kidney disease (eGFR \<60ml/min/1.73m2)
* Patients with established atherosclerotic vascular disease (via patient health records or selfreport) including cerebrovascular disease (prior stroke or transient ischemic attack), cardiovascular disease (myocardial infarction, acute coronary syndrome, stable angina, or revascularization), or peripheral arterial disease (symptomatic and/or ankle brachial index \<0.9)
* Primary prevention patients with multiple risk factors and Framingham risk score \>30%
Exclusion Criteria
* Unwilling or unable to participate in regular follow-up visits
* Pregnancy
* Undergoing existing medication therapy adherence clinic conducted by the Pharmacy Unit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Klinik Kesihatan Puchong
UNKNOWN
Klinik Kesihatan Kelana Jaya
UNKNOWN
Klinik Kesihatan Shah Alam Seksyen 7
UNKNOWN
Klinik Kesihatan Shah Alam Seksyen 9
UNKNOWN
Klinik Kesihatan Taman Medan
UNKNOWN
Klinik Kesihatan Seri Kembangan
UNKNOWN
Monash University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaun Lee Wen Huey
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shaun Lee
Role: PRINCIPAL_INVESTIGATOR
Monash University Malaysia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shaun Lee
Subang Jaya, Selangor, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PxES-CAR2+
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.